{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T13:45:34Z","timestamp":1746539134846},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Despite guideline recommendations, the limited benefits and failure of prophylactic treatment in patients with migraine have been reported. This study aimed to estimate the incremental burden (i.e., healthcare resource use and cost) of disease in patients who received at least one prophylactic treatment compared to those who did not.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study analyzed the Health Insurance Review and Assessment Service database, which covers the entire population of Korea from December 2014 to November 2019. We included adult patients with migraine (\u226518\u2009years) who had \u22651 claim with migraine diagnosis (G43) or received \u22651 prescription of triptan or ergotamine between December 2015 and November 2018. We defined two groups: (1) migraine patients who received at least one prophylactic treatment (prophylaxis group) and (2) migraine patients who never received prophylactic treatments (non-prophylaxis group). We performed propensity score matching to balance the baseline covariates between the two groups. In a matched cohort, we estimated healthcare resource use and costs in terms of outpatient visits, outpatient visits to neurologists, emergency department (ED) visits, and hospitalizations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After matching, 633,709 and 633,709 patients were identified in the prophylaxis and non-prophylaxis groups, respectively. The healthcare resource utilization was significantly higher in the prophylaxis group than in the non-prophylaxis group in terms of the number of outpatient visits (2.34 vs 1.70), outpatient visits to neurologists (2.23 vs 1.61), ED visits (1.07 vs 1.05), and hospitalizations (1.12 vs 1.09) (all <jats:italic>P<\/jats:italic>\u2009&lt;\u2009\u00a00.05). The estimated annual costs per patient were significantly higher in the prophylaxis group than in the non-prophylaxis group for outpatient (102.37 USD vs. 62.46 USD), neurology outpatient (141.80 USD vs. 120.30 USD), and ED visits (550.51 USD vs. 234.14 USD) and hospitalization (817.01 USD vs. 645.97 USD) (all <jats:italic>P<\/jats:italic>\u2009&lt;\u2009\u00a00.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Migraine patients who received \u22651 prophylactic treatment had a higher burden of disease than migraine patients who received no prophylaxis. This indicates that despite migraine prophylaxis, the migraine-related disease burden remains high, and more efficient migraine prophylaxis strategies are needed.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-022-08191-z","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T22:26:19Z","timestamp":1657664779000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The disease burden of migraine patients receiving prophylactic treatments in Korea: a population-based claims database analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Seonyoung","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sola","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hae Sun","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,12]]},"reference":[{"key":"8191_CR1","first-page":"1","volume":"38","author":"M Arnold","year":"2018","unstructured":"Arnold M. Headache classification committee of the international headache society (IHS) the international classification of headache disorders. Cephalalgia. 2018;38:1\u2013211.","journal-title":"Cephalalgia"},{"key":"8191_CR2","first-page":"215","volume":"59","author":"TJ Song","year":"2019","unstructured":"Song TJ, Cho SJ, Kim WJ, Yang KI, Yun CH, Chu MK. Sex differences in prevalence, symptoms, impact, and psychiatric comorbidities in migraine and probable migraine: a population-based study. Headache: the journal of head and face. Pain. 2019;59:215\u201323.","journal-title":"Pain"},{"key":"8191_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-020-01117-2","volume":"21","author":"S Yu","year":"2020","unstructured":"Yu S, Zhang Y, Yao Y, Cao H. Migraine treatment and healthcare costs: retrospective analysis of the China health insurance research association (CHIRA) database. J Headache Pain. 2020;21:1\u20137.","journal-title":"J Headache Pain"},{"key":"8191_CR4","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"LJ Stovner","year":"2018","unstructured":"Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, Al-Raddadi RM, et al. Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2018;17:954\u201376.","journal-title":"Lancet Neurol"},{"key":"8191_CR5","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","volume":"16","author":"VL Feigin","year":"2017","unstructured":"Feigin VL, Abajobir AA, Abate KH, Abd-Allah F, Abdulle AM, Abera SF, et al. Global, regional, and national burden of neurological disorders during 1990\u20132015: a systematic analysis for the global burden of disease study 2015. Lancet Neurol. 2017;16:877\u201397.","journal-title":"Lancet Neurol"},{"key":"8191_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-020-01213-3","volume":"22","author":"BK Kim","year":"2021","unstructured":"Kim BK, Chu MK, Yu SJ, Dell\u2019Agenello G, Han JH, Cho SJ. Burden of migraine and unmet needs from the patients\u2019 perspective: a survey across 11 specialized headache clinics in Korea. J Headache Pain. 2021;22:1\u201310.","journal-title":"J Headache Pain"},{"key":"8191_CR7","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.ncl.2019.07.004","volume":"37","author":"SK Parikh","year":"2019","unstructured":"Parikh SK, Silberstein SD. Preventive treatment for episodic migraine. Neurol Clin. 2019;37:753\u201370.","journal-title":"Neurol Clin"},{"key":"8191_CR8","first-page":"1","volume":"59","author":"Society AH","year":"2019","unstructured":"Society AH. The American headache society position statement on integrating new migraine treatments into clinical practice. Headache: the journal of head and face. Pain. 2019;59:1\u201318.","journal-title":"Pain"},{"key":"8191_CR9","volume-title":"Treatment guideline of pharmacological preventive therapy for episodic migraine","author":"Society KH","year":"2019","unstructured":"Society KH. Treatment guideline of pharmacological preventive therapy for episodic migraine. Korea: Medical Publisher Co.; 2019."},{"key":"8191_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-018-0839-1","volume":"19","author":"Z Katsarava","year":"2018","unstructured":"Katsarava Z, Mania M, Lampl C, Herberhold J, Steiner TJ. Poor medical care for people with migraine in Europe\u2013evidence from the Eurolight study. J Headache Pain. 2018;19:1\u20139.","journal-title":"J Headache Pain"},{"key":"8191_CR11","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1111\/j.1526-4610.2008.01088.x","volume":"48","author":"SJ Wang","year":"2008","unstructured":"Wang SJ, Chung CS, Chankrachang S, Ravishankar K, Merican JS, Salazar G, et al. Migraine disability awareness campaign in Asia: migraine assessment for prophylaxis. Headache. 2008;48:1356\u201365.","journal-title":"Headache"},{"key":"8191_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-020-01839-5","volume":"20","author":"M Delussi","year":"2020","unstructured":"Delussi M, Vecchio E, Libro G, Quitadamo S, De Tommaso M. Failure of preventive treatments in migraine: an observational retrospective study in a tertiary headache center. BMC Neurol. 2020;20:1\u201312.","journal-title":"BMC Neurol"},{"key":"8191_CR13","doi-asserted-by":"publisher","first-page":"e2014008","DOI":"10.4178\/epih\/e2014008","volume":"36","author":"L Kim","year":"2014","unstructured":"Kim L, Kim J-A, Kim S. A guide for the utilization of health insurance review and assessment service national patient samples. Epidemiol Health. 2014;36:e2014008. https:\/\/doi.org\/10.4178\/epih\/e2014008.","journal-title":"Epidemiol Health"},{"key":"8191_CR14","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/j.1526-4610.2012.02185.x","volume":"52","author":"E Loder","year":"2012","unstructured":"Loder E, Burch R, Rizzoli P. The 2012 AHS\/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012;52:930\u201345.","journal-title":"Headache"},{"key":"8191_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-019-0964-5","volume":"20","author":"MA Korolainen","year":"2019","unstructured":"Korolainen MA, Kurki S, Lassenius MI, Toppila I, Costa-Scharplatz M, Purmonen T, et al. Burden of migraine in Finland: health care resource use, sick-leaves and comorbidities in occupational health care. J Headache Pain. 2019;20:1\u201316.","journal-title":"J Headache Pain"},{"key":"8191_CR16","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.37765\/ajmc.2020.42543","volume":"26","author":"M Polson","year":"2020","unstructured":"Polson M, Williams TD, Speicher LC, Mwamburi M, Staats PS, Tenaglia AT. Concomitant medical conditions and total cost of care in patients with migraine: a real-world claims analysis. Am J Manag Care. 2020;26:S3\u20137.","journal-title":"Am J Manag Care"},{"key":"8191_CR17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343\u20139.","journal-title":"Neurology"},{"key":"8191_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-018-0907-6","volume":"19","author":"P Vo","year":"2018","unstructured":"Vo P, Fang J, Bilitou A, Laflamme AK, Gupta S. Patients\u2019 perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom. J Headache Pain. 2018;19:1\u201311.","journal-title":"J Headache Pain"},{"key":"8191_CR19","volume-title":"Gatekeeping in German primary health care-impacts on coordination of care, quality indicators and ambulatory costs","author":"SM Hofmann","year":"2016","unstructured":"Hofmann SM, Muehlenweg AM. Gatekeeping in German primary health care-impacts on coordination of care, quality indicators and ambulatory costs. Germany: Universitaet Duisburg-Essen, Competent in Competition and Health; 2016."},{"key":"8191_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.healthpol.2005.05.003","volume":"76","author":"MW Kroneman","year":"2006","unstructured":"Kroneman MW, Maarse H, Van Der Zee J. Direct access in primary care and patient satisfaction: a European study. Health Policy. 2006;76:72\u20139.","journal-title":"Health Policy"},{"key":"8191_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-019-1027-7","volume":"20","author":"C Piccinni","year":"2019","unstructured":"Piccinni C, Cevoli S, Ronconi G, Dondi L, Calabria S, Pedrini A, et al. A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years. J Headache Pain. 2019;20:1\u20139.","journal-title":"J Headache Pain"},{"key":"8191_CR22","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1177\/0333102419851855","volume":"39","author":"JL Meyers","year":"2019","unstructured":"Meyers JL, Davis KL, Lenz RA, Sakai F, Xue F. Treatment patterns and characteristics of patients with migraine in Japan: a retrospective analysis of health insurance claims data. Cephalalgia. 2019;39:1518\u201334.","journal-title":"Cephalalgia"},{"key":"8191_CR23","first-page":"973","volume":"21","author":"SD Silberstein","year":"2015","unstructured":"Silberstein SD. Preventive migraine treatment. Continuum. 2015;21:973.","journal-title":"Continuum"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-08191-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-022-08191-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-08191-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T22:30:13Z","timestamp":1657665013000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-022-08191-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,12]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["8191"],"URL":"https:\/\/doi.org\/10.1186\/s12913-022-08191-z","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,12]]},"assertion":[{"value":"15 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted according to the guidelines of the Declaration of Helsinki, and approved by Pusan National University Institutional Review Board (PNU IRB\/2020_76_HR). The need for Informed Consent was waived by the PNU IRB because datasets are completely anonymous.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"902"}}